Douglas R Johnston, Christopher Mehta, S Christopher Malaisrie, Abigail S Baldridge, Duc T Pham, Benjamin Bryner, Melissa G Medina, Stephen Chiu, Kevin E Hodges, Patrick M McCarthy
{"title":"Edwards Magna 生物瓣膜的植入尺寸和结构性瓣膜退化。","authors":"Douglas R Johnston, Christopher Mehta, S Christopher Malaisrie, Abigail S Baldridge, Duc T Pham, Benjamin Bryner, Melissa G Medina, Stephen Chiu, Kevin E Hodges, Patrick M McCarthy","doi":"10.21037/acs-2024-aae-26","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The desire of patients to avoid anticoagulation, together with the potential of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR), have resulted in the increasing use of bioprosthetic valves for aortic valve replacement (AVR). While patient-prosthesis mismatch (PPM) is known to be an adverse risk after AVR, few studies have addressed the effect of PPM on valve durability. This study evaluates the role of valve size and hemodynamics on long term durability after AVR with a Magna bioprosthesis.</p><p><strong>Methods: </strong>We performed a retrospective, single-center evaluation of patients who underwent a surgical AVR procedure between June 2004 through December 2022 using the Magna bioprosthesis. Perioperative information and long-term follow-up data were sourced from the institution's Society for Thoracic Surgeons Adult Cardiac Surgery Registry and outcomes database. Cumulative incidence of freedom from reintervention were estimated accounting for competing events. Group comparisons used Gray's test.</p><p><strong>Results: </strong>Among 2,100 patients, the mean patient age was 69 years (range, 22-95 years), of whom 98% had native aortic valve disease, 32.5% had concomitant coronary bypass grafting, and 19% had mitral valve surgery. Median follow-up was 5.8 (1.9-9.4) years, during which 116 reinterventions were performed, including 74 explants and 42 VIV procedures. Nine hundred and twenty-eight patients died prior to reintervention. Incidence of all cause reintervention was 1.2%, 4.5%, and 11.7% at 5, 10, and 15 years, respectively. Smaller valve size was associated with worse survival (P<0.001), but not with reintervention. Higher mean gradient at implant was associated with increased late reintervention [sub-distribution hazard ratio: 1.016; 95% confidence interval (CI): 1.005 to 1.028; P=0.0047, n=1,661].</p><p><strong>Conclusions: </strong>While reintervention rates are low for the Magna prosthesis at 15 years, the analysis is confounded by the competing risk of death. PPM, as reflected physiologically by elevated post-operative valve gradients, portends an increased risk of intervention. Further study is necessary to elucidate the mechanism of early stenosis in patients who progress to reintervention.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148762/pdf/","citationCount":"0","resultStr":"{\"title\":\"Implanted size and structural valve deterioration in the Edwards Magna bioprosthesis.\",\"authors\":\"Douglas R Johnston, Christopher Mehta, S Christopher Malaisrie, Abigail S Baldridge, Duc T Pham, Benjamin Bryner, Melissa G Medina, Stephen Chiu, Kevin E Hodges, Patrick M McCarthy\",\"doi\":\"10.21037/acs-2024-aae-26\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The desire of patients to avoid anticoagulation, together with the potential of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR), have resulted in the increasing use of bioprosthetic valves for aortic valve replacement (AVR). While patient-prosthesis mismatch (PPM) is known to be an adverse risk after AVR, few studies have addressed the effect of PPM on valve durability. This study evaluates the role of valve size and hemodynamics on long term durability after AVR with a Magna bioprosthesis.</p><p><strong>Methods: </strong>We performed a retrospective, single-center evaluation of patients who underwent a surgical AVR procedure between June 2004 through December 2022 using the Magna bioprosthesis. Perioperative information and long-term follow-up data were sourced from the institution's Society for Thoracic Surgeons Adult Cardiac Surgery Registry and outcomes database. Cumulative incidence of freedom from reintervention were estimated accounting for competing events. Group comparisons used Gray's test.</p><p><strong>Results: </strong>Among 2,100 patients, the mean patient age was 69 years (range, 22-95 years), of whom 98% had native aortic valve disease, 32.5% had concomitant coronary bypass grafting, and 19% had mitral valve surgery. Median follow-up was 5.8 (1.9-9.4) years, during which 116 reinterventions were performed, including 74 explants and 42 VIV procedures. Nine hundred and twenty-eight patients died prior to reintervention. Incidence of all cause reintervention was 1.2%, 4.5%, and 11.7% at 5, 10, and 15 years, respectively. Smaller valve size was associated with worse survival (P<0.001), but not with reintervention. Higher mean gradient at implant was associated with increased late reintervention [sub-distribution hazard ratio: 1.016; 95% confidence interval (CI): 1.005 to 1.028; P=0.0047, n=1,661].</p><p><strong>Conclusions: </strong>While reintervention rates are low for the Magna prosthesis at 15 years, the analysis is confounded by the competing risk of death. PPM, as reflected physiologically by elevated post-operative valve gradients, portends an increased risk of intervention. Further study is necessary to elucidate the mechanism of early stenosis in patients who progress to reintervention.</p>\",\"PeriodicalId\":3,\"journal\":{\"name\":\"ACS Applied Electronic Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148762/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Electronic Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/acs-2024-aae-26\",\"RegionNum\":3,\"RegionCategory\":\"材料科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ENGINEERING, ELECTRICAL & ELECTRONIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/acs-2024-aae-26","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 0
摘要
背景:患者希望避免抗凝,加上瓣中瓣(VIV)经导管主动脉瓣置换术(TAVR)的潜力,导致主动脉瓣置换术(AVR)中越来越多地使用生物人工瓣膜。众所周知,患者与人工瓣膜不匹配(PPM)是主动脉瓣置换术后的不良风险之一,但很少有研究探讨 PPM 对瓣膜耐久性的影响。本研究评估了瓣膜尺寸和血流动力学对使用 Magna 生物前列腺假体进行 AVR 术后长期耐久性的影响:我们对 2004 年 6 月至 2022 年 12 月期间使用 Magna 生物人工瓣膜进行手术房室重建的患者进行了回顾性单中心评估。围手术期信息和长期随访数据来自该机构的胸外科医师协会成人心脏手术登记和结果数据库。在考虑竞争事件的情况下,估算了无再介入的累积发生率。组间比较采用格雷氏试验:在2100名患者中,平均年龄为69岁(22-95岁),其中98%的患者患有原发性主动脉瓣疾病,32.5%的患者同时接受了冠状动脉旁路移植术,19%的患者接受了二尖瓣手术。中位随访时间为5.8(1.9-9.4)年,期间共进行了116次再干预,包括74次瓣膜置换和42次VIV手术。有928名患者在再次介入前死亡。5年、10年和15年时,各种原因的再介入发生率分别为1.2%、4.5%和11.7%。瓣膜尺寸越小,存活率越低(结论:瓣膜尺寸越小,存活率越高:虽然Magna人工瓣膜在15年后的再介入率较低,但死亡的竞争风险使分析受到了干扰。术后瓣膜梯度升高所反映的生理学上的PPM预示着干预风险的增加。有必要进行进一步研究,以阐明进展到再次介入的患者早期狭窄的机制。
Implanted size and structural valve deterioration in the Edwards Magna bioprosthesis.
Background: The desire of patients to avoid anticoagulation, together with the potential of valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR), have resulted in the increasing use of bioprosthetic valves for aortic valve replacement (AVR). While patient-prosthesis mismatch (PPM) is known to be an adverse risk after AVR, few studies have addressed the effect of PPM on valve durability. This study evaluates the role of valve size and hemodynamics on long term durability after AVR with a Magna bioprosthesis.
Methods: We performed a retrospective, single-center evaluation of patients who underwent a surgical AVR procedure between June 2004 through December 2022 using the Magna bioprosthesis. Perioperative information and long-term follow-up data were sourced from the institution's Society for Thoracic Surgeons Adult Cardiac Surgery Registry and outcomes database. Cumulative incidence of freedom from reintervention were estimated accounting for competing events. Group comparisons used Gray's test.
Results: Among 2,100 patients, the mean patient age was 69 years (range, 22-95 years), of whom 98% had native aortic valve disease, 32.5% had concomitant coronary bypass grafting, and 19% had mitral valve surgery. Median follow-up was 5.8 (1.9-9.4) years, during which 116 reinterventions were performed, including 74 explants and 42 VIV procedures. Nine hundred and twenty-eight patients died prior to reintervention. Incidence of all cause reintervention was 1.2%, 4.5%, and 11.7% at 5, 10, and 15 years, respectively. Smaller valve size was associated with worse survival (P<0.001), but not with reintervention. Higher mean gradient at implant was associated with increased late reintervention [sub-distribution hazard ratio: 1.016; 95% confidence interval (CI): 1.005 to 1.028; P=0.0047, n=1,661].
Conclusions: While reintervention rates are low for the Magna prosthesis at 15 years, the analysis is confounded by the competing risk of death. PPM, as reflected physiologically by elevated post-operative valve gradients, portends an increased risk of intervention. Further study is necessary to elucidate the mechanism of early stenosis in patients who progress to reintervention.